Výsledky vyhledávání - "Roberto Diaz-Beveridge"

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-6 (2021)
Nature Communications
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
NATURE COMMUNICATIONS
r-FISABIO. Repositorio Institucional de Producción Científica
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8921227b4094a6e83648a83acb6fbd70
https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e

Zobrazit plný text záznamu

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Autor: Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Richard F. Riedel, Silvia Stacchiotti, Elizabeth T. Loggers, Kristen N. Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F. Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K. Schwartz, James L. Chen, Hari Deshpande, Elizabeth J. Davis, Garth Nicholas, Stefan Gröschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herráez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A. Van Tine, Katharina Götze, Filomena Mazzeo, Alexander Yakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A. Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R. Van Domelen, Christopher J. Walker, Hua Chang, Yosef Landesman, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Steven Attia

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

PURPOSE Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36acf0dab8ff58803f8bced57d71ecf0
http://hdl.handle.net/2445/190172

Zobrazit plný text záznamu

A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study

Publikováno v: Cancers
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancers, Vol 13, Iss 792, p 792 (2021)
Scientia
Volume 13
Issue 4
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7ae189020c1b9820dc01b3e6d0041c2
https://hdl.handle.net/10668/17307

Zobrazit plný text záznamu

Fears, feelings and findings about COVID-19 disease in hospitalized cancer patients in a tertiary Hospital in Spain

Autor: Benjamin Domingo Arrue, Domingo de Guzmán Ordaz Jurado, Rosa María Pastor Marí, Ana Tarazona Ortega, Lucía Fos Saus, Carlos Puchades Olmos, Alba Torres Martínez, Diego Soriano Polo, Guillermo Suay Montagud, Roberto Diaz Beveridge, Regina Gironés Sarrió, José Gómez Codina

IntroductionOn March 11th, COVID-19 was categorized as a pandemic. Risk factors for poor outcome in COVID-19 disease include personal history of cancer. The purpose of this research is to explore what do cancer patients know about COVID-19 and their

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46b39caadc964e783453823f38be4c83
https://doi.org/10.21203/rs.3.rs-34086/v1

Zobrazit plný text záznamu

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS)

Publikováno v: ONCOLOGIST
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Oncologist
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

BACKGROUND. Reference centers (RCs) are a key point for improving the survival of patients with soft‐tissue sarcomas (STS). The aim of this study was to evaluate selected items in the management of patients with STS, comparing results between RC an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6656227039b43271ddf5ff64ba693c5c
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2658

Zobrazit plný text záznamu

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

Publikováno v: Oncologist
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ONCOLOGIST
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Background Oncogenic KIT/PDGFRA signaling inhibition with imatinib achieves disease control in most patients with advanced/metastatic gastrointestinal stromal tumor (GIST), but resistance eventually develops after 20-24 months. Notably, a small subse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::523dc45abe56d4e6715b02e7023e6832
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10236

Zobrazit plný text záznamu

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Autor: Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant R Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf, Gabriela Cinat, Luis Enrique Fein, Michael Brown, Andrew Haydon, Adnan Khattak, Catriona McNeil, Phillip Parente, Jeremy Power, Rachel Roberts-Thomson, Shahneen Sandhu, Craig Underhill, Suresh Varma, Thomas Berger, Ahmad Awada, Nathalie Blockx, Veronique Buyse, Jeroen Mebis, Fábio André Franke, Sérgio Jobim de Azevedo, Nicolas Silva Lazaretti, Rahima Jamal, Catalin Mihalcioiu, Teresa Petrella, Kerry Savage, Xinni Song, Ralph Wong, Nina Dabelic, Stjepko Plestina, Zeljko Vojnovic, Petr Arenberger, Ivo Kocak, Ivana Krajsova, Eugen Kubala, Bohuslav Melichar, Yvetta Vantuchova, Kadri Putnik, Brigitte Dreno, Caroline Dutriaux, Jean-Jacques Grob, Pascal Joly, Jean-Philippe Lacour, Nicolas Meyer, Laurent Mortier, Luc Thomas, Michael Fluck, Thilo Gambichler, Jessica Hassel, Axel Hauschild, Paul Donnellan, John McCaffrey, Derek Power, Samuel Ariad, Gil Bar-Sela, Daniel Hendler, Ilan Ron, Jacob Schachter, Paolo Ascierto, Alfredo Berruti, Luca Bianchi, Vanna Chiarion Sileni, Francesco Cognetti, Riccardo Danielli, Anna Maria Di Giacomo, Luca Gianni, Aron Goldhirsch, Michele Guida, Paolo Marchetti, Paola Queirolo, Armando Santoro, Ellen Kapiteijn, Paula Ferreira, Georgy Gafton, Yulia Makarova, Zoran Andric, Nada Babovic, Darjana Jovanovic, Lidija Kandolf Sekulovic, Graham Cohen, Lydia Dreosti, Daniel Vorobiof, Maria Teresa Curiel Garcia, Roberto Diaz Beveridge, Margarita Majem Tarruella, Ivan Marquez Rodas, Jose-M Puliats Rodriguez, Antonio Rueda Dominguez, Marianne Maroti, Karin Papworth, Olivier Michielin, Ewan Brown, Pippa Corrie, Mark Harries, Satish Kumar, Agustin Martin-Clavijo, Mark Middleton, Poulam Patel, Toby Talbot, Sanjiv Agarwala, Paul Chapman, Robert Conry, Gary Doolittle, Tara Gangadhar, Sigrun Hallmeyer, Omid Hamid, Leonel Hernandez-Aya, Douglas Johnson, Frederic Kass, Tatjana Kolevska, Scott Lunin, April Salama, Branimir Sikic, Bradley Somer, David Spigel, Eric Whitman

Summary Background Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC–III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAF V600 muta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ca377ad3c682462789b57095f06c16
http://hdl.handle.net/11379/501841

Zobrazit plný text záznamu

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

Publikováno v: ANNALS OF ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Digital.CSIC. Repositorio Institucional del CSIC
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

[Background] Patients with relapsed unresectable osteosarcoma represents an unmet need, so active and safe systemic treatments are required. Fas cell surface death receptor and mammalian target of rapamycin pathways are implicated in progressing oste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11235569d2207eb33e79fc95de1fc417
https://hdl.handle.net/10668/11695

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání